Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Glenn Ishioka"'
Autor:
Surender Khurana, Elizabeth M Coyle, Jody Manischewitz, Lisa R King, Glenn Ishioka, Jeff Alexander, Jon Smith, Marc Gurwith, Hana Golding
Publikováno v:
PLoS ONE, Vol 10, Iss 1, p e0115476 (2015)
A Phase I trial conducted in 2009-2010 demonstrated that oral vaccination with a replication competent Ad4-H5 (A/Vietnam) vector with dosages ranging from 107-1011 viral particles was well tolerated. HA-specific T-cell responses were efficiently indu
Externí odkaz:
https://doaj.org/article/2f4a91ee8c2445f793525c6fccdf81f6
Autor:
Jeff Alexander, Jason Mendy, Lo Vang, Jenny B Avanzini, Fermin Garduno, Darly J Manayani, Glenn Ishioka, Peggy Farness, Li-Hua Ping, Ronald Swanstrom, Robert Parks, Hua-Xin Liao, Barton F Haynes, David C Montefiori, Celia LaBranche, Jonathan Smith, Marc Gurwith, Tim Mayall
Publikováno v:
PLoS ONE, Vol 8, Iss 12, p e82380 (2013)
There is a well-acknowledged need for an effective AIDS vaccine that protects against HIV-1 infection or limits in vivo viral replication. The objective of these studies is to develop a replication-competent, vaccine vector based on the adenovirus se
Externí odkaz:
https://doaj.org/article/688f74a69bab4601af81fd692d862712
Autor:
Jeff Alexander, Simone Ward, Jason Mendy, Darly J Manayani, Peggy Farness, Jenny B Avanzini, Ben Guenther, Fermin Garduno, Lily Jow, Victoria Snarsky, Glenn Ishioka, Xin Dong, Lo Vang, Mark J Newman, Tim Mayall
Publikováno v:
PLoS ONE, Vol 7, Iss 2, p e31177 (2012)
Influenza virus remains a significant health and social concern in part because of newly emerging strains, such as avian H5N1 virus. We have developed a prototype H5N1 vaccine using a recombinant, replication-competent Adenovirus serotype 4 (Ad4) vec
Externí odkaz:
https://doaj.org/article/942bade51b5e4d14aa02fb115e1fab4b
Autor:
Marc Gurwith, Mitchell B. Cohen, Beth D. Kirkpatrick, Jakub K. Simon, Marcelo B. Sztein, Douglas Haney, Jason B. Harris, Glenn Ishioka, Myron M. Levine, Caroline E. Lyon, Wilbur H. Chen, Michael Lock
Publikováno v:
Vaccine. 36:2768-2773
Background The single-dose live attenuated vaccine CVD 103-HgR protects against experimental Vibrio cholerae infection in cholera-naive adults for at least 6 months after vaccination. While vaccine-induced vibriocidal seroconversion is associated wit
Autor:
Tim Mayall, Richard J. Webby, Michael Lock, John E Ervin, Richard N. Greenberg, Glenn Ishioka, Eve M Taylor, Peter F. Wright, Marc Gurwith, John J. Treanor, Jeff Alexander, Cynthia Strout
Publikováno v:
The Lancet Infectious Diseases
Summary Background Replication-competent virus vector vaccines might have advantages compared with non-replicating vector vaccines. We tested the safety and immunogenicity of an oral adenovirus serotype 4 vector vaccine candidate (Ad4-H5-Vtn) express
Autor:
James N. Ingle, John Fikes, Christopher J. Krco, Lavakumar Karyampudi, Glenn Ishioka, Soldano Ferrone, Keith L. Knutson, Courtney L. Erskine, Kimberly R. Kalli, Courtney Formicola, Mary L. Disis, Peter J. Wettstein, Melanie Beebe, Matthew J. Maurer, Lynn C. Hartmann
Publikováno v:
Clinical Cancer Research. 16:825-834
Purpose: Over the past two decades, there has been significant interest in targeting HER-2/neu in immune-based approaches for the treatment of HER-2/neu+ cancers. For example, peptide vaccination using a CD8 T cell–activating HER-2/neu epitope (ami
Autor:
Aleksandra Marinkovic-Petrovic, Marie-France del Guercio, Drew Hannaman, Jeff Alexander, Erika Assarsson, Scott Southwood, Stephani Stewart, Glenn Ishioka, Les Walker, Alessandro Sette, Mark Newman, Lo Vang, Claire Crimi, Pamuk Bilsel, Jason Botten, Vivek Chitnis
Publikováno v:
Vaccine. 28:664-672
The goal of the present study was to design a vaccine that would provide universal protection against infection of humans with diverse influenza A viruses. Accordingly, protein sequences from influenza A virus strains currently in circulation (H1N1,
Autor:
John Fikes, Melanie Beebe, Peter J. Wettstein, Matthew J. Maurer, Chao Yu, Glenn Ishioka, Lynn C. Hartmann, Courtney L. Erskine, Lavakumar Karyampudi, James N. Ingle, Karin Goodman, Keith L. Knutson, Mary L. Disis, Aziza Nassar, Christopher J. Krco, Kimberly R. Kalli
Publikováno v:
Cancer Immunology, Immunotherapy. 59:161-171
CD4 T cells are important for anti-tumor immune responses. Aside from their role in the activation of CD8 T cells, CD4 T cells also mediate anti-tumor immune responses by recruiting innate immune effectors into the tumor microenvironment. Thus, the s
Autor:
Alessandra Franco, Jeff Alexander, Luciano Adorini, Howard M. Grey, Stephen M. Hedrick, Ken Snoke, Dawne M. Page, Glenn Ishioka, Jörg Ruppert, Alessandro Sette
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::067f4fbaa28e8abbefbd38d9e59262bf
https://doi.org/10.1159/000423971
https://doi.org/10.1159/000423971
Autor:
J. Fikes, A. Sette, M. Newman, J Alexander, R. Chesnut, Glenn Ishioka, S. Tangri, J. Sidney, B. Livingston, D. McKinney
Publikováno v:
Tissue Antigens. 59:443-451
In this review we describe the methods and processes that our group have developed while aiming to test and design multiepitope vaccines for infectious diseases and cancer. Testing the performance of vaccines composed of epitopes restricted by human